• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Do Cyclooxygenase Inhibitors Alter the Antiplatelet Effects of Aspirin?

Do Cyclooxygenase Inhibitors Alter the Antiplatelet Effects of Aspirin?

April 13, 2005 By Arthritis Center

Aspirin has been shown to reduce the risks of heart attack and stroke. Aspirin and other non-steroidal inflammatory drugs work by inhibiting the actions of an enzyme in platelets known as COX-1. Aspirin, however, is unique in that it irreversibly inhibits COX-1 production in platelets, whereas other NSAIDs have only a temporary inhibitory effect. Thus among the NSAIDs, aspirin alone is thought to possess cardioprotective effects.

Aspirin and the other NSAIDs bind to the same portion of the COX-1 enzyme. Because many patients are treated concomitantly with both aspirin and other NSAIDs, it was of interest to determine whether such a regimen would negate the beneficial effects of aspirin through competitive inhibition. That is, the NSAID might block aspirin from interacting with COX-1. In this study, Catella-Lawson et al (N Engl J Med. 2001 Dec 20;345(25):1844-6) investigated this potential interaction between aspirin and commonly prescribed arthritis therapies.

Methods:

Volunteers were administered one of the following regimens for six days: aspirin (81 mg) followed by ibuprofen (400 mg) two hours later and the same medications in the reverse order; aspirin followed by acetaminophen (1000 mg) two hours later and the same medications in the reverse order; aspirin followed by the COX-2 inhibitor rofecoxib (25 mg every morning) two hours later and the same medications in the reverse order; enteric-coated aspirin followed by ibuprofen (400 mg three times a day) two hours later; and enteric-coated aspirin followed by delayed-release diclofenac (75 mg twice a day) two hours later.

Results:

The concomitant administration of acetaminophen and diclofenac did not affect the effects of aspirin on COX-1 inhibition and platelet aggregation. As expected, the COX-2 inhibitor rofecoxib also did not affect the pharmacodynamics of aspirin. COX-2 inhibitors bind to a pocket on the COX-2 enzyme that is not present on the COX-1 enzyme. However, treatment with ibuprofen either as a single dose or as multiple daily doses inhibited the aggregation of platelets and COX-1 inhibition by aspirin. Acetaminophen was found to be a very weak COX-1 inhibitor and according to the authors “it is perhaps not surprising that acetaminophen also fails to modify the antiplatelet action of aspirin.” That diclofenac did not negate the effects of aspirin while ibuprofen did is somewhat surprising. This may be due to the “lower potency and shorter duration of action of the diclofenac regimen.” The authors speculate that another NSAID, indomethacin, may competitively inhibit the cardioprotective effects of aspirin to a degree similar to ibuprofen.

Conclusions:

Ibuprofen may limit the cardioprotective effects of aspirin. This may extend to other NSAIDs as well. Diclofenac, acetaminophen and rofecoxib have very little modulating effect on the cardioprotective effects of aspirin.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy